Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

European Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2008, Pages 335-336

  Rotger, Margalida ^a   Telenti, Amalio ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6; EFAVIRENZ;

AFRICA; ALLELE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG WITHDRAWAL; GENDER; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEUROTOXICITY; NOTE; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL;

AFRICA; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DRUG MONITORING; GENOTYPE; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 40049094339     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0440-z     Document Type: Note

References (15)

1. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488-1495
2. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300
3. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993
4. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415
5. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73:20-30
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75
7. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM (2005) Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143:714-721
8. Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, Perez-Alvarez N, Gomez G, Burger D, Clotet B (2005) Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 38:560-565
9. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and*26. Clin Infect Dis 45:1230-1237
10. Hasse B, Gunthard HF, Bleiber G, Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22-e23
11. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400
12. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1-5
13. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557-566
14. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-13266
15. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C (2008) High prevelance of the CYP2B651G → T (*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zinbabwe. Eur J Clin Pharmacol in press